We partner with both small and large companies to develop and commercialize innovative treatments for patients globally. Through our collaborations, we accelerate development and broaden market access of innovative medicines to patients who are suffering life-threatening diseases. We operate with a very strong sense of urgency and a commitment to quality and compliance.
Angus J. Grant, Ph.D., Chief Business Executive
We have a highly integrated approach to selecting, developing, and sustaining partnerships. At BeiGene, Corporate Strategy, Product Strategy & Valuation, Clinical & BD Insights, Search & Evaluation, Transactions, and Alliance Management work as an integrated Strategy & Partnering team to drive innovation with our partners.
We are committed to partnering with the best minds in academia, biotech and pharma around the world to bring the highest quality and most innovative therapies to billions more people. We team up with partners who share our patient-centric vision and our unwavering commitment to transformational science.
Partnerships are essential for our mission to improve access and treatment outcomes for patients worldwide. Our partners help us create patient value through scientific discovery and clinical differentiation; drive innovation and access in China, Europe, the United States, and new markets; and accelerate technology-innovation and clinical-stage assets. Our integrated Strategy and Partnering team strives to identify best partners and craft bespoke deals that create long-lasting, mutually-beneficial partnerships.
Areas of Interest
Areas of interest
We actively seek out partners that have
Differentiated assets in hem-onc and solid tumors
I&I assets in diseases with high unmet needs
Innovative technologies and clinical-stage assets
Opportunities to access large and growing market in China
Opportunities to establish or expand access in the United States, Europe, and new markets
BeiGene was founded around innovative science, and this mindset continues today. Our scale and cutting-edge capabilities allow us to work with partners to tackle a wide array of medical challenges, across the product lifecycle and disease spectrum.
Global Clinical Leadership
With approximately 4.6 million1 new cancer patients in 2020, China has as many cancer patients as the U.S. and EU combined and is the second largest pharmaceutical market in the world by revenue. It’s a dynamic market with expanding reimbursement, increasing patient affordability, regulatory reforms and international quality standards.
We have repeatedly demonstrated our ability to successfully file drug approval applications in the U.S. and elsewhere based on the quality of our global China-inclusive studies. These studies come with significant time savings and enable innovative designs.
Science-Medical-Based Commercial Team
BeiGene is building one of the largest science and medical based oncology commercial team in China, and a robust and growing commercial team in leading markets across the world. We have had five successful launches in our first four years as a commercial-stage company.
Fit-for-Purpose Alliance Management
We believe one of our key differentiators is our commitment to designing our alliances based on the specific scientific, clinical, and commercial needs of the partnered asset/technology. Each of our teams are well-equipped to execute on our partnerships, and we strive to instill the values of teamwork, transparent communication, and scientific-based and agile decision-making across all of BeiGene.
Working with organizations that share our patient-centric vision and our commitment to exceptional science ensures that together, BeiGene and our partners, are able to get treatments to those in need around the world.